Oncotarget

Research Papers:

Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using magnetic resonance imaging: The value of contrast-enhanced and diffusion weighted imaging

Chuangen Guo, Xiao Chen, Zhongqiu Wang, Wenbo Xiao, Qidong Wang, Ke Sun and Xiaoling Zhuge _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:42962-42973. https://doi.org/10.18632/oncotarget.17309

Metrics: PDF 1226 views  |   HTML 1641 views  |   ?  


Abstract

Chuangen Guo1,*, Xiao Chen2,3,*, Zhongqiu Wang2, Wenbo Xiao1, Qidong Wang1, Ke Sun4 and Xiaoling Zhuge5

1Department of Radiology, The First Affiliated Hospital, College of Medicine Zhejiang University, Hangzhou 310003, China

2Department of Radiology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 2100029, China

3Division of Nephrology, Zhongshan Hospital Fudan University, Shanghai 200032, China

4Department of Pathology, The First Affiliated Hospital, College of Medicine Zhejiang University, Hangzhou 310003, China

5Department of Laboratory Medicine, The First Affiliated Hospital, College of Medicine Zhejiang University, Hangzhou 310003, China

*These authors have contributed equally to this work

Correspondence to:

Xiaoling Zhuge, email: xlzhgzy@qq.com

Chuangen Guo, email: zyyfy001@sina.cn

Keywords: pancreatic ductal adenocarcinoma, pancreatic neuroendocrine carcinoma, magnetic resonance imaging, diffusion-weighted imaging

Received: December 28, 2016    Accepted: April 05, 2017    Published: April 21, 2017

ABSTRACT

Pancreatic neuroendocrine carcinoma (PNEC) is often misdiagnosed as pancreatic ductal adenocarcinoma (PDAC). This retrospective study differentiated PNEC from PDAC using magnetic resonance imaging (MRI), including contrast-enhanced (CE) and diffusion-weighted imaging (DWI). Clinical data and MRI findings, including the T1/T2 signal, tumor boundary, size, enhancement degree, and apparent diffusion coefficient (ADC), were compared between 37 PDACs and 13 PNECs. Boundaries were more poorly defined in PDAC than PNEC (97.3% vs. 61.5%, p<0.01). Hyper-/isointensity was more common in PNEC than PDAC at the arterial (38.5% vs. 0.0), portal (46.2% vs. 2.7%) and delayed phases (46.2% vs. 5.4%) (all p<0.01). Lymph node metastasis (97.3% vs. 61.5%, p<0.01) and local invasion/distant metastasis (86.5% vs. 46.2%, p<0.01) were more common in PDAC than PNEC. Enhancement degree via CE-MRI was higher in PNEC than PDAC at the arterial and portal phases (p<0.01). PNEC ADC values were lower than those of normal pancreatic parenchyma (p<0.01) and PDAC (p<0.01). Arterial and portal phase signal intensity ratios and ADC values showed the largest areas under the receiver operating characteristic curve and good sensitivities (92.1%–97.2%) and specificities (76.9%–92.3%) for differentiating PNEC from PDAC. Thus the enhancement degree at the arterial and portal phases and the ADC values may be useful for differentiating PNEC from PDAC using MRI.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17309